JP4782378B2 - リンパ球異常増殖疾患の診断方法 - Google Patents
リンパ球異常増殖疾患の診断方法 Download PDFInfo
- Publication number
- JP4782378B2 JP4782378B2 JP2003566246A JP2003566246A JP4782378B2 JP 4782378 B2 JP4782378 B2 JP 4782378B2 JP 2003566246 A JP2003566246 A JP 2003566246A JP 2003566246 A JP2003566246 A JP 2003566246A JP 4782378 B2 JP4782378 B2 JP 4782378B2
- Authority
- JP
- Japan
- Prior art keywords
- chromosome
- nav3
- gene
- ctcl
- cell lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 45
- 210000004698 lymphocyte Anatomy 0.000 title description 33
- 230000002159 abnormal effect Effects 0.000 title description 26
- 230000035755 proliferation Effects 0.000 title description 5
- 210000000349 chromosome Anatomy 0.000 claims description 170
- 201000005962 mycosis fungoides Diseases 0.000 claims description 91
- 230000005945 translocation Effects 0.000 claims description 89
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 57
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 57
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 57
- 108090000623 proteins and genes Proteins 0.000 claims description 57
- 239000000523 sample Substances 0.000 claims description 38
- 208000009359 Sezary Syndrome Diseases 0.000 claims description 24
- 208000021388 Sezary disease Diseases 0.000 claims description 24
- 239000012634 fragment Substances 0.000 claims description 24
- 101100348015 Homo sapiens NAV3 gene Proteins 0.000 claims description 22
- 101150026704 NAV3 gene Proteins 0.000 claims description 22
- 102100030464 Neuron navigator 3 Human genes 0.000 claims description 17
- 238000012217 deletion Methods 0.000 claims description 16
- 230000037430 deletion Effects 0.000 claims description 16
- 208000028561 Primary cutaneous T-cell lymphoma Diseases 0.000 claims description 13
- 230000007547 defect Effects 0.000 claims description 13
- 238000001514 detection method Methods 0.000 claims description 13
- 238000011161 development Methods 0.000 claims description 12
- 208000032839 leukemia Diseases 0.000 claims description 11
- 101710145274 Neuron navigator 3 Proteins 0.000 claims description 10
- 239000012472 biological sample Substances 0.000 claims description 10
- 238000003745 diagnosis Methods 0.000 claims description 9
- 238000007901 in situ hybridization Methods 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 5
- 238000009007 Diagnostic Kit Methods 0.000 claims description 3
- 238000001228 spectrum Methods 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000010422 painting Methods 0.000 claims description 2
- 238000012800 visualization Methods 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 74
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 48
- 201000010099 disease Diseases 0.000 description 41
- 230000002759 chromosomal effect Effects 0.000 description 39
- 238000004458 analytical method Methods 0.000 description 27
- 210000002230 centromere Anatomy 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 20
- 230000003463 hyperproliferative effect Effects 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 10
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 101000582005 Homo sapiens Neuron navigator 3 Proteins 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 230000001537 neural effect Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- 208000035970 Chromosome Breakpoints Diseases 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000002559 cytogenic effect Effects 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 206010025323 Lymphomas Diseases 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 238000013399 early diagnosis Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 101100316120 Caenorhabditis elegans unc-53 gene Proteins 0.000 description 3
- 208000031404 Chromosome Aberrations Diseases 0.000 description 3
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000764238 Isis Species 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 3
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 208000034951 Genetic Translocation Diseases 0.000 description 2
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000212749 Zesius chrysomallus Species 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000012224 gene deletion Methods 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 101150090724 3 gene Proteins 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102000049982 HMGA2 Human genes 0.000 description 1
- 108700039143 HMGA2 Proteins 0.000 description 1
- 102100029009 High mobility group protein HMG-I/HMG-Y Human genes 0.000 description 1
- 102100028999 High mobility group protein HMGI-C Human genes 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000986380 Homo sapiens High mobility group protein HMG-I/HMG-Y Proteins 0.000 description 1
- 101000986379 Homo sapiens High mobility group protein HMGI-C Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 208000018501 Lymphatic disease Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- 102000009645 Mitochondrial Aldehyde Dehydrogenase Human genes 0.000 description 1
- 108010009513 Mitochondrial Aldehyde Dehydrogenase Proteins 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101150114311 PAWR gene Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 229920000037 Polyproline Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000024530 Primary cutaneous B-cell lymphoma Diseases 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 108700025690 abl Genes Proteins 0.000 description 1
- ZCHPKWUIAASXPV-UHFFFAOYSA-N acetic acid;methanol Chemical compound OC.CC(O)=O ZCHPKWUIAASXPV-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000000701 chemical imaging Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 201000004528 gastrointestinal lymphoma Diseases 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 238000012333 histopathological diagnosis Methods 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 230000002895 hyperchromatic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20020132A FI20020132A7 (fi) | 2002-01-24 | 2002-01-24 | Diagnostisia ja terapeuttisia menetelmiä |
| FI20020132 | 2002-01-24 | ||
| FI20021617 | 2002-09-10 | ||
| FI20021617A FI113666B (fi) | 2002-01-24 | 2002-09-10 | Menetelmiä, joissa käytetään kromosomin 12 spesifisiä katkoskohtia ja/tai neuroninavigaattori 3 -geeniä ihon primaaristen T-solulymfoomien diagnosoimiseksi ja taudin etenemisen seuraamiseksi tai ennustamiseksi, sekä näiden katkoskohtien ja geenien käyttö |
| PCT/FI2003/000061 WO2003066898A1 (en) | 2002-01-24 | 2003-01-24 | A method for the diagnosis of lymphoproliferative diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005518790A JP2005518790A (ja) | 2005-06-30 |
| JP2005518790A5 JP2005518790A5 (enExample) | 2006-02-09 |
| JP4782378B2 true JP4782378B2 (ja) | 2011-09-28 |
Family
ID=26161265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003566246A Expired - Fee Related JP4782378B2 (ja) | 2002-01-24 | 2003-01-24 | リンパ球異常増殖疾患の診断方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7803532B2 (enExample) |
| EP (1) | EP1476567A1 (enExample) |
| JP (1) | JP4782378B2 (enExample) |
| AU (1) | AU2003201630A1 (enExample) |
| CA (1) | CA2474446A1 (enExample) |
| FI (1) | FI113666B (enExample) |
| WO (1) | WO2003066898A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0878552A1 (en) | 1997-05-13 | 1998-11-18 | Erasmus Universiteit Rotterdam | Molecular detection of chromosome aberrations |
| JP2002513587A (ja) | 1998-05-04 | 2002-05-14 | ダコ エー エス | 染色体異常を検出するための方法およびプローブ |
| WO2007071829A2 (en) | 2005-12-22 | 2007-06-28 | Dermagene Oy | Methods and means related to diseases |
| JP5523103B2 (ja) * | 2006-11-13 | 2014-06-18 | ヘルシンギン・ユリオピストン・ラハストト | 第１２染色体における遺伝子異常を含む方法および使用 |
| ES2534769T3 (es) | 2007-09-20 | 2015-04-28 | Valipharma | Diagnóstico de linfoma de linfocitos B |
| WO2009126804A2 (en) * | 2008-04-11 | 2009-10-15 | The Regents Of The University Of Colorado, A Body Corporate | Expression of kir in human cancer cells as a biomarker for immuno-escape and cancer metastasis |
| CA2740351A1 (en) * | 2008-10-20 | 2010-04-29 | Pharmatest Services Ltd. | Methods and uses involving genetic aberrations of nav3 and aberrant expression of multiple genes |
| EP4034567A4 (en) * | 2019-09-23 | 2023-07-05 | Neonc Technologies, Inc. | PHARMACEUTICAL COMPOSITIONS WITH POH DERIVATIVES |
| JP7258224B2 (ja) | 2020-03-16 | 2023-04-14 | 株式会社マンダム | Ｔ細胞性リンパ腫の指標の検出方法、及びその利用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6007994A (en) * | 1995-12-22 | 1999-12-28 | Yale University | Multiparametric fluorescence in situ hybridization |
| ES2534769T3 (es) * | 2007-09-20 | 2015-04-28 | Valipharma | Diagnóstico de linfoma de linfocitos B |
-
2002
- 2002-09-10 FI FI20021617A patent/FI113666B/fi not_active IP Right Cessation
-
2003
- 2003-01-24 JP JP2003566246A patent/JP4782378B2/ja not_active Expired - Fee Related
- 2003-01-24 AU AU2003201630A patent/AU2003201630A1/en not_active Abandoned
- 2003-01-24 CA CA 2474446 patent/CA2474446A1/en not_active Abandoned
- 2003-01-24 WO PCT/FI2003/000061 patent/WO2003066898A1/en not_active Ceased
- 2003-01-24 US US10/502,638 patent/US7803532B2/en not_active Expired - Fee Related
- 2003-01-24 EP EP03700329A patent/EP1476567A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US7803532B2 (en) | 2010-09-28 |
| EP1476567A1 (en) | 2004-11-17 |
| US20050221309A1 (en) | 2005-10-06 |
| JP2005518790A (ja) | 2005-06-30 |
| WO2003066898A1 (en) | 2003-08-14 |
| FI20021617A0 (fi) | 2002-09-10 |
| AU2003201630A1 (en) | 2003-09-02 |
| FI113666B (fi) | 2004-05-31 |
| CA2474446A1 (en) | 2003-08-14 |
| FI20021617A7 (fi) | 2003-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2882759C (en) | Detection of the ntrk1-mprip gene fusion for cancer diagnosis | |
| DK2456889T3 (en) | Markers of endometrial cancer | |
| AU664834B2 (en) | Gene mutated in colorectal cancer of humans | |
| Subramaniam et al. | Tissue, cell type, and breast cancer stage‐specific expression of a TGF‐β inducible early transcription factor gene | |
| US20130203064A1 (en) | NOVEL ALTERNATIVE SPLICING VARIANT OF OATP1B3 mRNA | |
| JP2003518920A (ja) | 新規なヒト遺伝子および遺伝子発現産物 | |
| US20020076735A1 (en) | Diagnostic and therapeutic methods using molecules differentially expressed in cancer cells | |
| JPH11510393A (ja) | 白血病マーカーとしておよび乳癌の予後において有用な単離された核酸分子 | |
| Sagaert et al. | MALT1 and BCL10 aberrations in MALT lymphomas and their effect on the expression of BCL10 in the tumour cells | |
| JP2001524802A (ja) | ２０ｑ１３アンプリコンからの遺伝子及びそれらの使用 | |
| JP4782378B2 (ja) | リンパ球異常増殖疾患の診断方法 | |
| KR102788019B1 (ko) | 췌장암의 진단용 조성물 | |
| KR20060048684A (ko) | 암의 진단 및 치료 방법 | |
| EP0966531B1 (en) | Tazarotene-induced gene 3 (tig3) | |
| Cocchi et al. | The utility of FISH analysis in the diagnosis of BCOR-rearranged sarcomas | |
| KR101492024B1 (ko) | 전이성 뇌종양 진단용 마커 | |
| US20040180349A1 (en) | Diagnosis and treatment of cancer involving the notch pathway | |
| US6277968B1 (en) | Human uroplakin II gene and methods for detecting and classifying bladder cancer via human uroplakin genes | |
| JP5734947B2 (ja) | 異常型ミトコンドリアｄｎａ、関連融合転写物および翻訳産物、並びにそのハイブリダイゼーションプローブ | |
| JPH08500731A (ja) | 診断法 | |
| JP2003528630A (ja) | ヒト遺伝子および発現産物 | |
| KR20050004076A (ko) | 암의 평가 및 치료 방법 | |
| WO2021172315A1 (ja) | Ｌａｍｃ２－ｎｒ６ａ１スプライシングバリアント及びその翻訳産物 | |
| US7355025B2 (en) | Marker molecules associated with lung tumors | |
| KR20180137049A (ko) | 삼중음성 유방암 특이적 단백질분해조절 효소 유전자를 포함하는 삼중음성 유방암 바이오마커 및 이를 이용한 삼중음성 유방암 진단을 위한 정보제공방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051215 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051215 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20051227 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20051227 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20061024 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20061024 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080812 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081111 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081118 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081211 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091222 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100323 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100330 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100622 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20100622 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100622 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110201 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110427 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20110427 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110427 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110621 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110707 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140715 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |